AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Hesai Group shares rise 3.30% intraday after Ascletis Pharma Inc. announced positive Phase III study results for denifanstat (ASC40).
ByAinvest
Thursday, Sep 18, 2025 3:42 pm ET1min read
Hesai Group rose 3.30% intraday, with Ascletis Pharma Inc. presenting positive Phase III study results of denifanstat (ASC40) for the treatment of moderate to severe acne vulgaris. The study met all primary, key secondary, and secondary efficacy endpoints, demonstrating a favorable safety and tolerability profile. The company is planning to submit an NDA for denifanstat (ASC40) for the treatment of moderate to severe acne, with encouraging feedback from the China National Medical Products Administration (NMPA).
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet